aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
aTyr Pharma, Inc. (ATYR)
Company Research
Source: GlobeNewswire
SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Eric Benevich to the Company’s Board of Directors, effective as of December 10, 2024. Mr. Benevich currently serves as Chief Commercial Officer at Neurocrine Biosciences, Inc. (Neurocrine). “We are excited to welcome Eric Benevich to the Board of Directors,” said Timothy P. Coughlin, Chairman of the Board of aTyr. “His extensive background bringing new products to market and the knowledge and expertise he has gained from both building and leading commercial activities at biopharmaceutical companies will be an invaluable resource as aTyr continues its evolution towards commercialization.” Mr. Benevich has served as Chief Commercial Officer of Neurocrine since May 2015 and is responsible for a
Show less
Read more
Impact Snapshot
Event Time:
ATYR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATYR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATYR alerts
High impacting aTyr Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
ATYR
News
- aTyr Pharma, Inc. (NASDAQ:ATYR) is a favorite amongst institutional investors who own 57% [Yahoo! Finance]Yahoo! Finance
- aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Atyr PHARMA INC (NASDAQ: ATYR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.MarketBeat
- aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis [Yahoo! Finance]Yahoo! Finance
- aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary SarcoidosisGlobeNewswire
ATYR
Earnings
- 8/13/24 - Miss
ATYR
Sec Filings
- 12/23/24 - Form 424B5
- 12/23/24 - Form 8-K
- 12/12/24 - Form 4
- ATYR's page on the SEC website